Antibody Information

General Information of This Antibody

Antibody ID	ANI0LPFGY
Antibody Name	Anti-HER2 NJH395 mAb
Antibody Type	Monoclonal antibody (mAb)
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

NJH-395 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Patients with nonbreast HER2+ advanced malignancies.
Administration Dosage	5 dose cohorts (0.10-1.60 mg/kg).
*Related Clinical Trial*
NCT Number	NCT03696771	Clinical Status	Phase 1
Clinical Description	A phase 1, multicenter, open-label dose finding study of NJH395, administered intravenously in patients with non-breast HER2+ advanced malignancies.

References

Ref 1	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.